lol646ph Here is a roundup of state college football games played on Saturday, Nov. 23. Towson 45, Campbell 23: Tyrell Greene Jr. (Kenwood) rushed for three touchdowns to lead the visiting Tigers (7-5, 5-3 Colonial Athletic Association) over the Camels (3-9, 1-7). Towson extended its five-point lead by outscoring Campbell 24-7 in the fourth quarter. Devin Matthews added 134 rushing yards and a touchdown for the Tigers, who finished the regular-season on a three-game winning streak. Towson, which secured its second winning season in three years and its first seven-win season since 2019, will hope to get an at-large berth into the NCAA Football Championship Subdivision Playoffs. The selection show is Sunday at 12:30 p.m. on ESPN. Greene scored on a 7-yard run with 12:55 remaining, and after the Tigers’ Will Middleton intercepted a pass from Mike Chandler II, he broke loose for a 30-yard touchdown that stretched the Towson lead to 35-16 about 30 seconds later. Green also had a 3-yard TD run in the second quarter and finished with 41 yards on nine carries. Matthews carried the ball 15 times and scored on a 54-yard run for Towson. Seth Brown completed 10 of 15 passes for 156 yards with a touchdown and Christopher Watkins added a late TD run. Mark Biggins had a 1-yard touchdown run for Campbell. Chandler was 13 of 27 passing for 135 yards with a touchdown and two interceptions. Connor Lytton made 3 of 5 field goal attempts for the Camels. Morgan State 35, Howard 21: The host Bears (6-6, 3-2 Mid-Eastern Athletic Conference) put together a 28-0 run to pull away from the Bison (4-8, 1-4). Morgan State won three of its last four games. Kobe Muasau completed 19 of 24 passes for 202 yards and two touchdowns, Jason Collins rushed for 114 yards and two scores while catching seven passes for 89 yards and Myles Miree added 99 yards from scrimmage and a score to lead the Bears. SUNY-Morrisville 21, Stevenson 18: Host SUNY-Morrisville (7-4) took a 14-0 lead in the first quarter and never trailed Stevenson (5-6) in an Eastern College Athletic Conference Bowl game. The last time Stevenson appeared in the ECAC Bowl was 2017. SUNY-Morrisville extended its winning streak to four games.The suspect in the murder of UnitedHealth Group executive Brian Thompson was not a customer of the health insurer, a company spokesperson said today. Ivy League-educated Luigi Mangione was charged with murder on Dec. 9 for the killing of Thompson outside a Manhattan hotel before a company conference, following a five-day manhunt. Mangione suffered from chronic back pain that affected his daily life, according to friends and social media posts, though it is unclear whether his personal health played a role in the shooting. UnitedHealth does not have prior records for either Mangione or his mother, the spokesperson said. Thompson’s murder was met with shock across the industry, as well as an outpouring of anger from Americans struggling with healthcare costs and the complexities of U.S. health insurance. Public officials and healthcare executives have acknowledged the frustrations, but in the last few days have been more vocal in pushing back against social media glorification of an accused killer. In a New York Times opinion piece today, UnitedHealth Group CEO Andrew Witty said he understood public frustrations with the “flawed” U.S. healthcare system, but mourned Thompson’s killing and decried the “vitriol that has been directed at our colleagues who have been barraged by threats.” Thompson was CEO of the company’s large health insurance business. The New York Times reported that an internal New York City police report analyzing Mangione’s writings concluded that he viewed the killing as a justified response to what he believed to be corruption in the healthcare industry. In some circles, Mangione has been celebrated and more than a thousand donations have poured into an online fundraiser for his legal defense. “It’s representing a widespread anger that is felt by people in the middle class, in the working class and people who are well-to-do who also have trouble with their insurance company,” said Pepper Culpepper, a professor of government and public policy at Oxford University. ABC News and others reported today that a Florida woman was arrested after she allegedly ended a phone call with a representative from her insurer Blue Cross Blue Shield by saying the words “Delay, deny, depose. You people are next.” The words “deny,” “defend” and “depose” were carved into shell casings found at the Thompson murder scene, several news outlets reported, evoking the title of a book critical of the insurance industry published in 2010 titled “Delay, Deny, Defend: Why Insurance Companies Don’t Pay Claims and What You Can Do About It.” ‘INTENSELY PERSONAL AND VERY COMPLICATED’ “Health care is both intensely personal and very complicated, and the reasons behind coverage decisions are not well understood,” Witty wrote in his first public comments since the murder, noting that the U.S. healthcare system is a patchwork built over decades. “We share some of the responsibility for that. Together with employers, governments and others who pay for care, we need to improve how we explain what insurance covers and how decisions are made,” he wrote. Health insurance companies have come under sharp public scrutiny since Thompson’s Dec. 4 murder, and shares of UnitedHealth alone have fallen nearly 15%. It isn’t clear if the recent events “represent a watershed moment” that could catalyze change in the industry, said Morningstar analyst Julie Utterback. “You can definitely feel the potential for some kind of change in the air.” The healthcare sector has reassessed security measures due to an uptick in violent crime the last 18 months, Reuters reported, with UnitedHealth and rivals CVS Health and Cigna removing photos of their leadership from their websites following the shooting. Instead of boosting security for executives, insurers should manage public perception of their services, said Culpepper, adding that many Americans believe big health insurers refuse to cover needed care in an effort to bolster revenue. “This sort of ambient discontent around health insurance in the United States will not go away until it starts to be addressed.”

Benson had seven rebounds for the Bearcats (3-6). Tymu Chenery shot 7 for 12, including 3 for 5 from beyond the arc to add 18 points. Wes Peterson had 10 points and shot 3 of 4 from the field and 4 for 6 from the line. Gavin Walsh's layup with 2 seconds remaining in regulation tied it for Binghamton. Jamal Fuller led the way for the Sharks (3-6) with 27 points and 10 rebounds. Terell Strickland added 17 points and eight assists for LIU. Malachi Davis also had 12 points. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .Syrian government services come to ‘complete halt’ as workers stay at home

Biliary Tract Cancer Pipeline Therapeutics Assessment Report 2024 (Updated) 11-30-2024 01:32 PM CET | Health & Medicine Press release from: DelveInsight Business Research LLP Biliary Tract Cancer Pipeline DelveInsight's, "Biliary Tract Cancers Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Biliary Tract Cancers Pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Biliary Tract Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Biliary Tract Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from the Biliary Tract Cancer Pipeline Report •In November 2024:- Unicancer- This is a Phase 3, multicentre, randomised, open-label trial to evaluate whether the introduction of molecular targeted therapy (MTT) as maintenance after 4 cycles of standard-of-care first-line systemic therapy (1L SoC) is superior to continuation of 1L-SoC in the treatment of patients with ABC. The trial is composed of two phases: (i) An initial screening phase to identify a suitable patient population, and (ii) a randomised comparative trial. •In November 2024:- AstraZeneca- A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers •DelveInsight's Biliary Tract Cancer pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for treatment. •The leading Biliary Tract Cancer Companies such as Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee's Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee's Pharmaceutical Limited, and others. •Promising Biliary Tract Cancer Therapies such as Nivolumab, Gemcitabine, and S-1, Gemcitabine, cisplatin, Pembrolizumab, Sargramostim, oxaliplatin, KN035 plus Gemcitabine & oxaliplatin, and others. Stay ahead with the most recent pipeline outlook for Biliary Tract Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Biliary Tract Cancer Treatment Drugs- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Biliary Tract Cancer Emerging Drugs Profile •MRG 002: Miracogen MRG 002, is an antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. An open-label, single-arm, multi-center, phase II Clinical Study of MRG002 are conducted by Miracogen for the treatment of patients with HER2-positive unresectable, locally advanced or metastatic biliary tract cancer. MRG002 is administrated by an IV infusion of 2.6 mg/kg on Day 1 of every 3 weeks (21-day cycle). •Disitamab vedotin: Yantai Rongchang Pharmaceutical Disitamab Vedotin is an antibody-drug conjugate with a drug structure consisting of three parts Anti-human epidermal growth factor receptor 2 extracellular domain (HER2 ECD) antibody; Linker (MC-Val-Cit-PAB, Linker); and Cytotoxic Monomethyl Auristatin E (Monomethyl Auristatin E, MMAE). This product is white to light yellow loose body, after reconstitution, it is colorless to light yellow clear liquid. •Envafolimab: Alphamab Oncology Envafolimab is a PD-L1 single-domain antibody Fc fusion protein independently developed by Alphamab. Based on the unique design, Envafolimab has advantages in safety, convenience and compliance, and can be used for patients who are not suitable for intravenous infusion with a lower medical cost. On March 30, 2020, Alphamab, 3D Medicines and Simcere reached a three-way strategic collaboration. Alphamab, as the original research party, is responsible for production and quality, 3D Medicines is responsible for global clinical development in the field of oncology, registration and commercialization abroad, and Simcere is responsible for the exclusive commercial promotion of the product in mainland China. •DKN-01: Leap Therapeutics DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein. DKK1 modulates the Wnt/Beta-catenin and PI3kinase/AKT signaling pathways and has an important role in promoting tumor proliferation, metastasis, angiogenesis, and in mediating an immune suppressive tumor microenvironment through enhancing the activity of myeloid-derived suppressor cells and downregulating NK cell ligands on tumor cells. Explore groundbreaking therapies and clinical trials in the Biliary Tract Cancer Pipeline. Access DelveInsight's detailed report now! @ New Biliary Tract Cancer Drugs- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Biliary Tract Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration •Intravenous •Subcutaneous •Oral •Intramuscular Products have been categorized under various Molecule types such as •Monoclonal antibody •Small molecule •Peptide Unveil the future of Biliary Tract Cancer treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Biliary Tract Cancer Market Drivers and Barriers- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Scope of the Biliary Tract Cancer Pipeline Report •Coverage- Global •Biliary Tract Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination •Biliary Tract Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III •Biliary Tract Cancer Companies- Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee's Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee's Pharmaceutical Limited, and others •Biliary Tract Cancer Therapies- Nivolumab, Gemcitabine, and S-1, Gemcitabine, cisplatin, Pembrolizumab, Sargramostim, oxaliplatin, KN035 plus Gemcitabine & oxaliplatin, and others. Get the latest on Biliary Tract Cancer therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Biliary Tract Cancer Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Table of Content 1.Introduction 2.Executive Summary 3.Biliary Tract Cancer: Overview 4.Pipeline Therapeutics 5.Therapeutic Assessment 6.Biliary Tract Cancer- DelveInsight's Analytical Perspective 7.Late Stage Products (Phase III) 8.Envafolimab: Alphamab Oncology 9.Drug profiles in the detailed report..... 10.Mid Stage Products (Phase II/III) 11.SMT-NK: SMT bio Co., Ltd. 12.Drug profiles in the detailed report..... 13.Mid Stage Products (Phase II) 14.HA121-28: CSPC ZhongQi Pharmaceutical Technology 15.Drug profiles in the detailed report..... 16.Early Stage Products (Phase I) 17.ZKAB001: Lee's Pharmaceutical Limited 18.Drug profiles in the detailed report..... 19.Preclinical and Discovery Stage Products 20.Drug name: Company name 21.Drug profiles in the detailed report..... 22.Inactive Products 23.Biliary Tract Cancer Key Companies 24.Biliary Tract Cancer Key Products 25.Biliary Tract Cancer- Unmet Needs 26.Biliary Tract Cancer- Market Drivers and Barriers 27.Biliary Tract Cancer- Future Perspectives and Conclusion 28.Biliary Tract Cancer Analyst Views 29.Biliary Tract Cancer Key Companies 30.Appendix List of Top Selling Market Research Reports in 2024 carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market surgical lasers market- https://www.delveinsight.com/report-store/surgical-lasers-market transcatheter treatment market - https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market scoliosis market - https://www.delveinsight.com/report-store/scoliosis-market stem cell market- https://www.delveinsight.com/report-store/stem-cell-market surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market lymphoedema market- https://www.delveinsight.com/report-store/lymphedema-market nk cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market mouth neoplasms market- https://www.delveinsight.com/sample-request/mouth-neoplasms-market somatotropin deficiency market - https://www.delveinsight.com/report-store/somatotropin-deficiency-market meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market seltorexant drug market- https://www.delveinsight.com/report-store/major-depressive-disorder-market surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market antibody drug conjugate market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market skin neoplasm market- https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: info@delveinsight.com Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: https://www.delveinsight.com/ This release was published on openPR.A day after he was discharged from a Ludhiana hospital, Punjab farmer leader Jagjit Singh Dallewal on Saturday sat on a fast-unto-death at the Khanauri border point to press for the acceptance of farmers' demands . Dallewal replaced Sukhjit Singh Hardojhande , who on Saturday ended his fast-unto-death, which he began on November 26. The decision to end Sukhjit's fast was taken in a meeting of farmer leaders at the border point. Hours before beginning his fast-unto-death on November 26, Dallewal was allegedly forcibly removed from the Khanauri border and taken to a hospital in Ludhiana. He was discharged on Friday evening. Addressing the media at the Khanauri border on Saturday, farmer leader Baldev Singh Sirsa said Sukhjit was requested to suspend his hunger strike as Dallewal has returned to the protest site where he sat on the fast-unto-death. He said initially, Dallewal was supposed to sit on the fast but the Punjab Police removed him from the protest site, following which Sukhjit observed the hunger strike. Marketing Marketing & Sales Strategies for Startups: From Concept to Conversion By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Office Productivity Advanced Excel Course - Financial Calculations & Excel Made Easy By - Anirudh Saraf, Founder- Saraf A & Associates, Chartered Accountant View Program Marketing Digital Marketing Masterclass by Neil Patel By - Neil Patel, Co-Founder and Author at Neil Patel Digital Digital Marketing Guru View Program Finance A2Z Of Finance: Finance Beginner Course By - elearnmarkets, Financial Education by StockEdge View Program Web Development C++ Fundamentals for Absolute Beginners By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development A Comprehensive ASP.NET Core MVC 6 Project Guide for 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital Marketing Masterclass by Pam Moore By - Pam Moore, Digital Transformation and Social Media Expert View Program Artificial Intelligence(AI) Tabnine AI Masterclass: Optimize Your Coding Efficiency By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance AI and Generative AI for Finance By - Hariom Tatsat, Vice President- Quantitative Analytics at Barclays View Program Artificial Intelligence(AI) Java Programming with ChatGPT: Learn using Generative AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Zero to Hero in Microsoft Excel: Complete Excel guide 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Mastering Microsoft Office: Word, Excel, PowerPoint, and 365 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Astrology Vastu Shastra Course By - Sachenkumar Rai, Vastu Shashtri View Program Artificial Intelligence(AI) Generative AI for Dynamic Java Web Applications with ChatGPT By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance A2Z Of Money By - elearnmarkets, Financial Education by StockEdge View Program Artificial Intelligence(AI) AI and Analytics based Business Strategy By - Tanusree De, Managing Director- Accenture Technology Lead, Trustworthy AI Center of Excellence: ATCI View Program Web Development Advanced Java Mastery: Object-Oriented Programming Techniques By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development JavaScript Essentials: Unlock AI-Driven Insights with ChatGPT By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Basics of Generative AI: Unveiling Tomorrow's Innovations By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) ChatGPT Mastery from Zero to Hero: The Complete AI Course By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development Mastering Full Stack Development: From Frontend to Backend Excellence By - Metla Sudha Sekhar, IT Specialist and Developer View Program Leadership Crafting a Powerful Startup Value Proposition By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program According to farmers, since Dallewal had started his fast-unto-death when he was in the Ludhiana hospital, he would continue it at the Khanauri border point. Sirsa accused the Punjab government of abducting Dallewal and keeping him in illegal custody under the pretext of carrying out his medical checkup. He claimed that no medical examination of Dallewal was carried out at the hospital. Another farmer leader will sit on a fast-unto-death after Dallewal sacrifices his life for farmers' cause, Sirsa said. Meanwhile, the Kisan Mazdoor Morcha held a meeting at the Shambhu border point in connection with their programme of marching to Delhi on December 6. KMM leader Sarwan Singh Pandher asked farmers to reach the Shambhu border point in large numbers. Among other issues, the farmers are also demanding the Centre hold talks with them to resolve their concerns, claiming the Union government has not held any talks with them since February 18. They have already given a call to march towards Delhi on December 6. The Samyukta Kisan Morcha (non-political) and the Kisan Mazdoor Morcha earlier announced plans to intensify their agitation in support of the farmers' various demands, including a legal guarantee for MSP , by starting a fast-unto-death. The farmers have been camping at Shambhu and Khanauri border points between Punjab and Haryana since February 13 after their march to Delhi was stopped by security forces. The protesters have accused the Centre of not taking steps to address their demands, claiming that it has not held any talks with them on their issues since February 18. Besides a legal guarantee for MSP, the farmers are demanding implementation of the Swaminathan Commission's recommendations, pension for farmers and farm labourers, farm debt waiver, reinstatement of the Land Acquisition Act, 2013, and compensation to the families of farmers who died during a previous agitation in 2020-21. (You can now subscribe to our Economic Times WhatsApp channel )NEW YORK , Dec. 9, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Enterprise Bancorp, Inc. (NASDAQ: EBTC ) , relating to the proposed merger with Independent Bank Corp. Under the terms of the agreement, shareholders of Enterprise will receive 0.60 shares of Independent, and $2.00 in cash, per share held. Click here for more https://monteverdelaw.com/case/enterprise-bancorp-inc-ebtc/ . It is free and there is no cost or obligation to you. NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask: About Monteverde & Associates PC Our firm litigates and has recovered money for shareholders...and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. No company, director or officer is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341. Contact: Juan Monteverde, Esq. MONTEVERDE & ASSOCIATES PC The Empire State Building 350 Fifth Ave. Suite 4740 New York, NY 10118 United States of America [email protected] Tel: (212) 971-1341 Attorney Advertising. (C) 2024 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC ( www.monteverdelaw.com ). Prior results do not guarantee a similar outcome with respect to any future matter. SOURCE Monteverde & Associates PC

B. Metzler seel. Sohn & Co. Holding AG Makes New $1.27 Million Investment in ScanSource, Inc. (NASDAQ:SCSC)

Off with the pixies: Musk’s X defectors discover their utopia

Costco, Walmart and more: 10 companies that offer part-time jobs with full-time benefits, according to a report

Syracuse, Albany each hoping to get right at expense of the otherReport: UCF HC Gus Malzahn to become Florida State OC